Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Inclusion Criteria11

• Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent.
• Elevated blood eosinophil count (BEC).
• Moderate to severe COPD with frequent exacerbations, defined as:
• A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year
• A post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post- bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values
• A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening
• COPD assessment test (CAT) score \>=10 at Visit 1.
• Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years.
• Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1.
• Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2).
• Male or eligible female participants.